In Sweden, about 50 000 people are living with type 1 diabetes and a majority use CGM/FGM and depend on insulin treatment to for their survival.
- Autoimmune disease
- Loss off endogennous insulin production
- Affects children, adolescents and adults
- Solely dependent on exogenous insulin treatment
- Insulin can be delivered via an insulin pen or pump
Approximately four percent of the Swedish population has type 2 diabetes and among those over the age of 75 at least ten percent have the disease.
- Life-style related and hereditary disease
- Insulin resistance is the hallmark of the disease
- Affects mainly adults but in increasing numbers also children
- In first hand oral antidiabetic drugs
- Exogenous insulin treatment in 20-30% of all patients
Acute & Long-term Complications
For both type 1 and type 2 diabetes, the disease includes a number of complications, both acute and long-term.
Acute complications can cause unconsciousness, coma and death. Long-term complications can cause heart disease, cerebrovascular disease, kidney ffailure, blindness and premature death.
Diabetes 3.0 - A New Paradigm for Diabetes Care
The insulin was detected a hundred years ago and before 1921, it was exceptional for people with Type 1 diabetes to live more than two years. The insulin is one of the twentieth century’s greatest medical discoveries and is still today the only effective treatment for people with Type 1 diabetes.
During 1980’s genetically engineered preparations appeared on the market that resembled the body’s own insulin with both short- and long-acting varieties. Around this time the first insulin pumps were introduced.
In the late 1990’s and early 2000’s blood glucose monitoring entered the market with CGM-sensors which enabled more self-care for people with type 1 diabetes. Today, with data from the CGM data there is a data and decision overload for the healthcare providers where the patients have to analyze continuous data manually in order to make daily decisions. Complicated data analysis and physiological modeling are issues as well.
Our solution to this data overload is a clinically validated digital service that generates automated analysis, monitoring, identification of root-causes, and treatment recommendations based on machine learning. DD Analytics see this as a paradigm shift where we use continuous data to provide better care and decision support for both healthcare providers and people with diabetes – enable daily decision. This is diabetes 3.0.
In Sweden, about 50 000 people are living with type 1 diabetes and a majority of whom use CGM/FGM. Globally, more than 5,5 million people live with type 1 diabetes who all depend on insulin treatment to survive. To control the treatment, they need to measure their blood sugar repeatedly per day and incorrect dosages can be directly fatal.
Diabetes in Sweden & Globally
However, there are no digital tools for automatically interoperating the data that is generated from CGM/FGM and thus no good decision support for either the individual or the health care. Our product is a “software as a service” and for the health care, we deliver a complete solution with automated analyzes, treatment proposals and a digital bridge to the patient. For the individual user we offer an application with analyzes of their blood glucose values.
Our goal is to revolutionize diabetes care with powerful digital tools based on big data and machine learning. We want to reach as many people with insulin-treated diabetes as possible and provide the health care system with tools to able optimal diabetes care. Our product generates automated interpretations of continuous blood glucose values and present the most probable root cause. Based on cluster data, we have created models for how to best achieve treatment goals.
DD Analytics offers a digital bridge between patients and healthcare providers which enables remote monitoring and visits with automatic and remote glucose data monitoring which highlights severe glucose alterations and identifies patients in need of urgent assistance.